FDA accepts Dupixent® (dupilumab) for review in children with moderate-to-severe asthma

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Suma Ramadas, PhD
Medical Affairs

Stacey Gandler
Brand Nourishment

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach

Joey Cohen
Medication Adherence

Matthew Durham
Omnidynamic Marketing

Frank Burrell
Scientific Storytelling

Amy Giles
Increasing Engagement

Brenda Snow
Authentic Patient Voice

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing